Lesli A Kiedrowski
Overview
Explore the profile of Lesli A Kiedrowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kobayashi Y, Chhoeu C, Li J, Price K, Kiedrowski L, Hutchins J, et al.
Nature
. 2022 Mar;
603(7900):335-342.
PMID: 35236983
RAS family members are the most frequently mutated oncogenes in human cancers. Although KRAS(G12C)-specific inhibitors show clinical activity in patients with cancer, there are no direct inhibitors of NRAS, HRAS...
12.
Rehman M, Kim C, Reuss J, Kiedrowski L, Garg R, Liu S
JCO Precis Oncol
. 2022 Jan;
5:939-942.
PMID: 34994624
No abstract available.
13.
Mortensen L, Ordulu Z, Dagogo-Jack I, Bossuyt V, Winters L, Taghian A, et al.
Oncologist
. 2021 Jun;
26(10):818-824.
PMID: 34176200
Enhanced understanding of the molecular events underlying oncogenesis has led to the development of "tumor-agnostic" treatment strategies, which aim to target a tumor's genomic profile regardless of its anatomic site...
14.
Thompson J, Carpenter E, Silva B, Rosenstein J, Chien A, Quinn K, et al.
JCO Precis Oncol
. 2021 Jun;
5.
PMID: 34095713
Materials And Methods: Patients with mNSCLC receiving pembrolizumab monotherapy or in combination with chemotherapy underwent a 74-gene next-generation sequencing panel on blood samples obtained at baseline and at 9 weeks....
15.
Ghatalia P, Smith C, Winer A, Gou J, Kiedrowski L, Slifker M, et al.
Front Oncol
. 2021 May;
11:674782.
PMID: 34026652
[This corrects the article DOI: 10.3389/fonc.2018.00652.].
16.
Schwartzberg L, Kiedrowski L
Ther Adv Med Oncol
. 2021 Apr;
13:17588359211006962.
PMID: 33868464
The oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib is approved for the treatment of patients with human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (mBC) and a germline breast cancer...
17.
Tanaka N, Lin J, Li C, Ryan M, Zhang J, Kiedrowski L, et al.
Cancer Discov
. 2021 Apr;
11(8):1913-1922.
PMID: 33824136
Mutant-selective KRAS inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in -mutant cancers, including non-small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resistance to...
18.
Jacob S, Kiedrowski L, Chae Y
Heliyon
. 2020 May;
6(5):e03841.
PMID: 32420470
Background: Reversion mutations of somatic BRCA mutations are an important source of resistance within ovarian cancer. Furthermore, these reversion mutations are known to change over the course of treatment. Better...
19.
Fairclough S, Kiedrowski L, Lin J, Zelichov O, Tarcic G, Stinchcombe T, et al.
Exp Hematol Oncol
. 2019 Oct;
8:24.
PMID: 31632838
Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of L792 mutations,...
20.
Maron S, Chase L, Lomnicki S, Kochanny S, Moore K, Joshi S, et al.
Clin Cancer Res
. 2019 Aug;
25(23):7098-7112.
PMID: 31427281
Purpose: Gastroesophageal adenocarcinoma (GEA) has a poor prognosis and few therapeutic options. Utilizing a 73-gene plasma-based next-generation sequencing (NGS) cell-free circulating tumor DNA (ctDNA-NGS) test, we sought to evaluate the...